◆ NeutralSPRY
ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
GlobeNewswire Inc.·
A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.
Read Full Article at GlobeNewswire Inc. →